What is J&J’s Manufacturing and Medicines Deal with Trump?

Global hospitals and healthcare company Johnson & Johnson (J&J) has signed a voluntary agreement with the Trump Administration to enhance patient access to medicines while reducing costs for millions of Americans.

The arrangement aligns the "innovation powerhouse" with US President Donald Trump’s demands for the pharmaceutical industry to adopt a most-favoured-nation pricing model.

It comes alongside J&J’s pledge to develop two additional facilities: a next-generation cell therapy manufacturing site in Pennsylvania and a state-of-the-art drug product facility in North Carolina.

A key element of the deal with the White House is that it provides its pharmaceutical products with a strategic exemption from newly-imposed tariffs.

The exemption depends on the company’s continued commitment to domestic production, effectively linking trade policy with industrial expansion.

J&J joins 14 other major pharmaceutical companies that have sought to stabilise their market position by striking deals with the White House.

The move is designed to ensure that their supply chains remain resilient against the backdrop of shifting international trade regulations and aggressive fiscal policy.

Pricing parity and platform access

Joaquin Duato, Chairman and CEO of Johnson & Johnson, says: “Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the US economy.

“I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in healthcare innovation.”

Joaquin emphasised that the agreement is a proactive response to the administration's directive to align domestic prices with those of other developed nations.

A central pillar of this strategy is the company's participation in TrumpRx.gov, a new direct-to-patient platform designed to allow patients to purchase medicines at significantly discounted rates.

Expanding the domestic industrial base

Beyond the digital marketplace, the agreement mandates that American patients access medicines at prices comparable to those in other developed economies.

This standard also extends to the Medicaid programme, ensuring fiscal sustainability for state-led healthcare initiatives.

This shift in pricing strategy is linked to J&J’s significant capital expenditure programme.

It is currently delivering on a previously announced US$55bn investment intended to bolster US manufacturing, research and technology through to early 2029.

Over the past 10 months, the firm has allocated funds specifically to ensure the company can manufacture the majority of its advanced medicines within the US, thereby reducing reliance on complex and often vulnerable international logistics networks.

Advanced therapies and regional growth

The manufacturing expansion is anchored by several high-profile projects in the American South and Northeast.

The company confirmed the development of a next-generation cell therapy manufacturing site in Pennsylvania and a state-of-the-art drug product facility in North Carolina.

While specific locations have yet to be disclosed, they represent a significant scaling of the company’s specialised production capabilities.

These sites will focus on the most advanced segments of the pharmaceutical portfolio, including oncology and neurological treatments.

This regional focus highlights the growing importance of the Life Sciences corridor, where infrastructure and a skilled workforce are readily available. It follows a pattern of rapid growth that has seen the company repeatedly increase its industrial commitments in these key states.

Strategic reshoring and fiscal incentives

In Wilson, North Carolina, construction is already under way on a US$2bn biologics manufacturing facility.

This project, which broke ground in 2025, is expected to create 5,000 skilled manufacturing and construction jobs.

In September, the group secured a 160,000sq ft biopharmaceutical manufacturing site in Holly Springs, with a US$2bn commitment over the next decade and 120 new specialised roles.

These investments are part of a broader industry trend where biopharma giants, including Novartis and Eli Lilly, are concentrating their manufacturing power in domestic hubs to meet the administration's "made in America" requirements.

The pharmaceutical companies that have agreed deals with the Trump Administration are:

• Johnson & Johnson
• Amgen
• Boehringer Ingelheim
• Bristol Myers Squibb
• Roche’s Genentech unit
• Gilead
• GSK
• Merck
• Novartis
• Sanofi
• Pfizer
• AstraZeneca
• EMD Serono
• Eli Lilly
• Novo Nordisk.

Securing the pharmaceutical supply chain

Only AbbVie and Regeneron remain as the final two companies from the original list of 17 targeted by the White House in July 2025.

For executives in the healthcare sector, the agreements represent a fundamental shift in how drug pricing and manufacturing are negotiated at the federal level.

J&J says: “The joint agreement meets the requests laid out by President Trump to the industry and provides the company’s pharmaceutical products an exemption from tariffs.”